Alent PLC Jumps Over 40% On £1.4bn Offer From Platform Specialty Products Corp

Platform Specialty Products Corp (NYSE: PAH) has made a £1.4bn offer for Alent PLC (LON: ALNT)

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Alent (LSE: ALNT) has fallen prey to Platform Specialty Products Corp after the US group made a 503p per share cash offer for FTSE 250 chemicals company.

Platform Specialty is a chemicals industry consolidation vehicle — a cash shell, in other words — which is going around acquiring undervalued businesses in the chemical industry, and rolling them into one group. 

The industry consolidator is willing to pay a hefty premium for its targets. Today’s offer for Alent is 49% above Alent’s Friday closing price of 338p. Alent’s shareholders will have the option to receive to receive shares in the new company in lieu of cash, up to 21.9% of the new entity’s issued share capital. 

And taking a portion of the offer in stock might be a sensible decision for Alent’s shareholders. Platform Specialty is well placed for long-term growth. 

Cost saving synergies

As a standalone company, City analysts had expected Alent to report earnings per share growth of around 10% per annum during 2016 and again in 2017. A combination of cost savings, revenue growth and margin expansion were expected to help Alent to grow pre-tax profit by 44% during the next two years.

As part of the larger Platform Specialty group, Alent should be able to achieve significant cost efficiencies, widening margins further. Platform reckons the combined group can achieve annual pre-tax cost synergies of at least $50m.

What’s more, Platform already owns MacDermid Inc., a specialty chemicals company that is a direct competitor of Alent’s US-based Enthone division that produces coatings for mobile phones and cars.

So, there’s more to this deal than just simple cost-saving synergies. Platform Specialty is removing a key competitor from the market and increasing production simultaneously.  However, as the deal will create a company that has a certain amount of control over key markets, it will require antitrust approval.

Rapid growth

Platform Specialty’s strategy is to buy companies that are leaders in niche businesses and require little capital investment. These companies usually generate a large amount of cash, which can be used for future bolt-on acquisitions to further boost growth. 

Indeed, over the past 12 months Platform Specialty has been on an acquisition spree, rolling up several smaller peers into its group structure.

This bolt-on strategy is set to achieve results. According to Wall Street analysts, before today’s announcement Platform Specialty’s earnings per share were on track to jump 83% during 2016 and 24% during 2017. The acquisition of Alent should only boost this growth.

Using Wall Street estimates, Platform Specialty’s shares that trade on the New York Stock Exchange are currently trading at a 2017 P/E of 11.7. 

The bottom line

All in all, Platform Specialty’s offer to buy Alent looks to be a great deal for shareholders. Shareholders are receiving a hefty premium for their shares, and the enlarged Platform Specialty will be well placed to generate rapid growth in the short-term as synergies flow through, and the company dominates key markets. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Just released: November’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

The Barclays share price has soared 72% in 2024. Is it too late for me to buy?

I'm looking for a bank stock to buy in early 2025. The 2024 Barclays share price rise has made the…

Read more »

Investing Articles

2 lessons from the HSBC share price soaring 159% in four years

Christopher Ruane looks at the incredible performance of the HSBC share price in recent years and learns some lessons for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

After a 2,342% rise, could this FTSE 250 stock keep going?

This FTSE 250 stock boasts a highly cash-generative business model and has been flying for years. Is it time to…

Read more »

Investing Articles

It’s up 70%, but the experts expect the IAG share price to climb still further

Why didn't I buy when I was convinced the IAG share price was likely to soar? And is there still…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »